Journal article

Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

Eric B Suhler, Glenn J Jaffe, Eric Fortin, Lyndell L Lim, Pauline T Merrill, Andrew D Dick, Antoine P Brezin, Quan Dong Nguyen, Jennifer E Thorne, Joachim Van Calster, Luca Cimino, Alfredo Adan, Hiroshi Goto, Toshikatsu Kaburaki, Michal Kramer, Albert T Vitale, Martina Kron, Alexandra P Song, Jianzhong Liu, Sophia Pathai Show all



PURPOSE: To evaluate long-term efficacy and safety of extended treatment with adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. DESIGN: Open-label, multicenter, phase 3 extension study (VISUAL III). PARTICIPANTS: Adults who had completed a randomized, placebo-controlled phase 3 parent trial (VISUAL I or II) without treatment failure (inactive uveitis) or who discontinued the study after meeting treatment failure criteria (active uveitis). METHODS: Patients received subcutaneous adalimumab 40 mg every other week. Data were collected for ≤ 362 weeks. Adverse events (AEs) were recorded until 70 days after the last dose. MAIN OUTCOME MEASURES: Long-term safety and..

View full abstract


Funding Acknowledgements

Sponsored by AbbVie, Inc., North Chicago, Illinois. The sponsor participated in study design and conduct; data management, analysis, and interpretation; and manuscript preparation, review, and approval. Medical writing support was provided by Catherine DeBrosse, PhD, of ICON (North Wales, PA), and was funded by AbbVie Inc.